Compare Franco-Nevada Corporation (FNV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Viatris Inc — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $45.36B), while Viatris Inc trades at $17.54 (market cap $20.05B). The key difference: Franco-Nevada Corporation is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Viatris Inc for 57 Days on average.
| FNV | VTRS | |
|---|---|---|
Market Cap | $45.36B | $20.05B |
Volume | 787,841 | 8,682,135 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $18.27 |
52-Week Low | $183.97 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $44.34B | $32.16B |
Dividend Yield | 0.75% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Viatris (VTRS) trades at $17.25, down 1.65% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue remains stable around $14.3B annually, though the company posted a net loss of $3.51B in 2025. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target, representing 28% upside potential.
The outlook suggests potential upside from current levels if earnings momentum continues, supported by strong cash flow generation and dividend payments. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the generic drug market. The stock appears reasonably valued with P/S of 1.36x, but the elevated P/E of 236x reflects current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
